Leveraging Proprietary CDO Platforms

Samsung Biologics has developed proprietary CDO platforms for bispecific antibodies, transient expression, developability assessment, cell line development, and modular glycosylation.

S-Dual™, an asymmetric bispecific antibody platform allows high yield and manufacturability. The platform has demonstrated high purity and lower residual impurities, with in vitro and in vivo assays showing comparable inhibition and tumor growth inhibition to reference antibodies. Furthermore, the S-DUAL™ bispecific antibodies have lower immunogenicity risk compared to trastuzumab and a positive control.

Their transient expression platform, S-CHOsient™, surpasses a commercial platform in terms of productivity and quality. It exhibits high productivity for monoclonal antibodies, Fc fusion proteins, and bispecific antibodies, ensuring qualified purity and intact formation.

Samsung Biologics also offers a developability assessment platform that efficiently assesses drug candidates based on specific criteria .The workflow includes various analytical techniques such as DSF, DLS, SE-HPLC, and CE-SDS, along with basic character study and stress confirmation.

Samsung Biologics' platforms aim to provide secure quality material provision for drug development, offering high-performing CHO-K1-based cell lines with improved productivity and viability. Learn how these robust platform offerings can help to optimize all stages of development and advance your project to clinic.